Your browser is no longer supported. Please, upgrade your browser.
Settings
MYGN Myriad Genetics, Inc. daily Stock Chart
MYGN [NASD]
Myriad Genetics, Inc.
Index- P/E143.98 EPS (ttm)0.18 Insider Own0.20% Shs Outstand77.31M Perf Week-4.23%
Market Cap2.01B Forward P/E14.17 EPS next Y1.84 Insider Trans-1.26% Shs Float72.51M Perf Month0.27%
Income13.50M PEG14.19 EPS next Q0.47 Inst Own- Short Float19.15% Perf Quarter-20.31%
Sales830.60M P/S2.43 EPS this Y334.40% Inst Trans- Short Ratio13.86 Perf Half Y-13.88%
Book/sh14.76 P/B1.77 EPS next Y4.97% ROA1.00% Target Price33.09 Perf Year-39.34%
Cash/sh1.94 P/C13.46 EPS next 5Y10.15% ROE1.50% 52W Range22.07 - 50.44 Perf YTD-10.35%
Dividend- P/FCF22.12 EPS past 5Y-4.90% ROI10.30% 52W High-48.33% Beta0.81
Dividend %- Quick Ratio2.90 Sales past 5Y4.70% Gross Margin76.40% 52W Low18.08% ATR1.15
Employees2400 Current Ratio3.10 Sales Q/Q18.30% Oper. Margin2.80% RSI (14)50.21 Volatility3.81% 4.99%
OptionableYes Debt/Eq0.24 EPS Q/Q-26.70% Profit Margin1.80% Rel Volume0.50 Prev Close25.72
ShortableYes LT Debt/Eq0.24 EarningsAug 06 AMC Payout0.00% Avg Volume1.00M Price26.06
Recom2.80 SMA201.43% SMA50-0.43% SMA200-17.66% Volume500,862 Change1.32%
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
Aug-10-16Reiterated Mizuho Neutral $34 → $22
Aug-10-16Downgrade Wells Fargo Outperform → Market Perform
Aug-10-16Downgrade Piper Jaffray Overweight → Neutral
Aug-10-16Downgrade Gabelli & Co Buy → Hold $46 → $32
Aug-10-16Downgrade Barclays Overweight → Equal Weight $50 → $24
Jul-09-19 09:34AM  Myriad Genetics Stock Is Falling as Enthusiasm Wanes Barrons.com
Jul-05-19 02:13PM  Heres What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Jul-02-19 02:55PM  Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues Zacks
Jun-27-19 07:28AM  Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer GlobeNewswire
Jun-25-19 07:07AM  Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer. GlobeNewswire
Jun-20-19 11:55AM  Read This Before Buying Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Simply Wall St.
Jun-19-19 07:05AM  Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan GlobeNewswire
Jun-11-19 08:00PM  Corporations Shouldn't Be Able to Patent Your DNA Bloomberg
Jun-06-19 09:31AM  Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report? Zacks
Jun-05-19 10:05AM  AngioDynamics Divests NAMIC Portfolio to Medline Industries Zacks
09:02AM  Myriad Genetics Announces Study Results Of myRisk Cancer Test Zacks
07:05AM  Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference GlobeNewswire
Jun-04-19 01:36PM  Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May Motley Fool
Jun-03-19 09:03AM  Myriad Genetics' (MYGN) POLO Study Shows Positive Results Zacks
07:05AM  Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology GlobeNewswire
Jun-02-19 09:00AM  BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) GlobeNewswire
May-30-19 07:07AM  Is Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Salary Justified? Simply Wall St.
May-21-19 08:14AM  Why Should You Hold on to Myriad Genetics (MYGN) Stock? Zacks
May-15-19 08:15AM  Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad? Motley Fool
May-14-19 07:05AM  Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-13-19 10:28PM  Edited Transcript of MYGN earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 07:05AM  New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy GlobeNewswire
May-08-19 04:53PM  Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today Motley Fool -21.35%
09:24AM  Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript Motley Fool
07:56AM  Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up Zacks
May-07-19 07:25PM  Myriad Genetics (MYGN) Beats Q3 Earnings Estimates Zacks
06:15PM  Myriad: Fiscal 3Q Earnings Snapshot Associated Press
04:05PM  Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results GlobeNewswire
May-01-19 04:05PM  Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight® GlobeNewswire
07:05AM  Myriad Genetics to Present at Two Upcoming Healthcare Conferences GlobeNewswire
Apr-30-19 11:17AM  EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer GlobeNewswire
10:32AM  Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? Zacks
Apr-29-19 04:11PM  Heres What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Apr-23-19 04:05PM  Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019 GlobeNewswire
10:20AM  3 Medical Product Stocks Set to Beat This Earnings Season Zacks
07:05AM  Myriad to Present Multiple Womens Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting GlobeNewswire
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
Apr-17-19 03:08PM  Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company Simply Wall St.
07:05AM  Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Councils 2019 Shatter List GlobeNewswire
Apr-09-19 07:05AM  Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test GlobeNewswire
Apr-05-19 09:33AM  Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck Zacks
Apr-04-19 08:56AM  Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake Zacks
07:05AM  Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership GlobeNewswire
Apr-02-19 07:05AM  Myriad Womens Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel Prenatal Tests GlobeNewswire
Mar-28-19 11:16AM  Myriad Genetics Gains on Innovation, New Reimbursements Zacks
Mar-21-19 07:05AM  Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting GlobeNewswire
Mar-18-19 09:03AM  Myriad's myPath Melanoma Test Awarded Medicare Coverage Zacks
Mar-14-19 08:01AM  Myriads myPath® Melanoma Test Receives Medicare Coverage GlobeNewswire +5.01%
Mar-12-19 10:11AM  Some Myriad Genetics (NASDAQ:MYGN) Shareholders Are Down 19% Simply Wall St. +6.41%
Mar-11-19 12:59PM  Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February Motley Fool
Mar-07-19 09:30AM  Why Is Myriad (MYGN) Down 0.5% Since Last Earnings Report? Zacks
07:15AM  Report: Exploring Fundamental Drivers Behind ArcelorMittal, Cohen & Steers, Myriad Genetics, Lexington Realty Trust, NorthWestern, and Chesapeake Utilities New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-06-19 07:05AM  Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine GlobeNewswire
Feb-26-19 01:10PM  Myriads BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib GlobeNewswire
Feb-22-19 07:05AM  Vectra® Study Published in the Journal Current Medical Research & Opinion GlobeNewswire
Feb-15-19 07:05AM  Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer GlobeNewswire
Feb-13-19 04:05PM  Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences GlobeNewswire
Feb-12-19 07:30AM  Detailed Research: Economic Perspectives on The Scotts Miracle-Gro, Forum Energy Technologies, Myriad Genetics, Ichor, Adesto Technologies, and Viad What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-11-19 07:05AM  Myriad Announces Prequel Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs GlobeNewswire
Feb-08-19 10:55AM  Edited Transcript of MYGN earnings conference call or presentation 5-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
07:05AM  Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting GlobeNewswire
Feb-06-19 09:07AM  Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates Zacks
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 11:08PM  Myriad Genetics Inc (MYGN) Q2 2019 Earnings Conference Call Transcript Motley Fool
10:07PM  Myriad Genetics Inc (MYGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:10PM  Myriad Genetics (MYGN) Q2 Earnings and Revenues Miss Estimates Zacks
06:03PM  Myriad: Fiscal 2Q Earnings Snapshot Associated Press
04:05PM  Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results GlobeNewswire
02:30PM  Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
Jan-31-19 10:17AM  Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings? Zacks
Jan-29-19 10:31AM  Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? Zacks
Jan-28-19 04:05PM  Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019 GlobeNewswire
Jan-24-19 05:17PM  A Bullish 2019 is Not a Con Zacks
Jan-18-19 08:06AM  Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now Zacks
Jan-11-19 09:30AM  MYGN vs. SWTUY: Which Stock Should Value Investors Buy Now? Zacks
09:30AM  Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This Year? Zacks
Jan-07-19 06:14PM  Epizyme to File NDA for Tazemetostat in Follicular Lymphoma Zacks -10.66%
04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks
10:10AM  Why the Earnings Surprise Streak Could Continue for Myriad (MYGN) Zacks
08:46AM  Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9% Zacks
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +6.93%
10:02AM  GeneSight® GUIDED Study Published in the Journal of Psychiatric Research GlobeNewswire
07:20AM  Investor Expectations to Drive Momentum within Ecolab, Arrow Electronics, Keysight Technologies, Myriad Genetics, Bristow Group, and IRSA Inversiones Y Representaciones S.A Discovering Underlying Factors of Influence GlobeNewswire
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks
08:50AM  Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks
Dec-31-18 07:05AM  Peter D. Meldrum (1947-2018) GlobeNewswire
Dec-29-18 08:19PM  [$$] Peter Meldrum Helped Found Myriad Genetics to Find Genes Linked to Inherited Cancers The Wall Street Journal
Dec-28-18 08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-27-18 09:56AM  Myriad Genetics Posts Positive Adjusted Vectra Test Data Zacks
08:25AM  AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions Zacks
07:05AM  Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-18 07:22AM  U.S. Political Tumult Shrouds Markets: 5 Safe Picks Zacks +5.07%
07:05AM  Myriad Announces Publication of Vectra® Study in Journal Rheumatology GlobeNewswire
Dec-25-18 09:46AM  Should Myriad Genetics, Inc. (NASDAQ:MYGN) Focus On Improving This Fundamental Metric? Simply Wall St.
Dec-21-18 01:36PM  6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger
Dec-20-18 08:38AM  Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base Zacks
Dec-19-18 01:10PM  BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZenecas Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer GlobeNewswire
07:05AM  EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer GlobeNewswire
Dec-14-18 10:12PM  Myriad Genetics, Inc. (MYGN): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-11-18 08:42AM  Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now Zacks
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McDade Ralph LPresident Myriad RBM, Inc.Mar 12Sale31.001,97561,225122,604Mar 12 05:56 PM